We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

關於Pfizer NOVUSCIENTIA Tablet

Novuscientia特別為今天的臨床醫生設計了一個移動應用程序。

Novuscientia is a mobile app designed especially for today’s clinicians. It is has been developed to be compatible with both iOS and Android and downloadable to both phone and tablets. It was created with the current practice of Filipino doctors in mind. Novuscientia is source of important and relevant information to help you get updated in your clinical practice, at your convenience. Online features of this medical app include cme videos on disease, on treatment approach as well as information on select Pfizer products. Slide presentations on the select topics can also be viewed online. It also links doctors to Pfizer’s Medical Information (MI) homepage to facilitate search for information through email request for articles that go straight to our MI hub. Drug information is also available to aid accurate prescriptions of preferred therapeutic regimen. Patient management tools such as risk calculators are also accessible. Offline features include scientific evidence behind current Pfizer portfolio and a bi-monthly release of articles and features. With regular notifications, you will be advised on new information that can be viewed in the app.

最新版本2.0更新日誌

Last updated on 2017年07月03日

Updates on the following features:

• Easier registration process flow
• Updated Terms of Service.

New Features:

• New content classification: CME, Events, News & Articles, Favorites
• Tag favourite content for faster access
• Filter and Search content
• New look and pleasant colour scheme
• New 5-page concise tutorial

翻譯中...

更多應用信息

最新版本

請求 Pfizer NOVUSCIENTIA Tablet 更新 2.0

上傳者

Abdullah Almorshdi

系統要求

Android 5.0+

更多

Pfizer NOVUSCIENTIA Tablet 螢幕截圖

語言
訂閱APKPure
第一時間獲取熱門安卓遊戲應用的首發體驗,最新資訊和玩法教程。
不,謝謝
訂閱
訂閱成功!
您已訂閱APKPure。
訂閱APKPure
第一時間獲取熱門安卓遊戲應用的首發體驗,最新資訊和玩法教程。
不,謝謝
訂閱
成功!
您已訂閱我們的郵件通知。